

EQA round: BIL1/24 - Bilirubin Neonatal

Deadline: 16.2.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(215) Bilirubin total	[μmol/L]				119							99	96	97
Sample A		207	17	8,3	119							99	96	97
(1) Jendrassik - Gróf		219	16	7,4	7	0	CVP	202	3	18%	165	239	7	
(2) DCA, DPD		201	11	5,6	88	0	CVP	202	3	18%	165	239	88	
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		238	12	4,9	9	0	CVPG	242	9,6	18%	198	286	0	
(7) Oxidation-reduction methods; (179) Siemens		232	22	9,5	6	0	CVPG	232	21	18%	190	274	0	
Other					9	0							4	
								1x 1/162, 3x 2/162, 1x 2/179, 1x 3, 1x 5, 2x 7						
Sample B		323	25	7,9	119							99	96	97
(1) Jendrassik - Gróf		331	22	6,6	7	0	CVP	315	4,5	18%	258	372	7	
(2) DCA, DPD		313	17	5,5	88	0	CVP	315	4,5	18%	258	372	88	
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		377	13	3,3	9	0	CVPG	376	13	18%	308	444	0	
(7) Oxidation-reduction methods; (179) Siemens		372	31	8,2	6	0	CVPG	372	30	18%	305	439	0	
Other					9	0							4	
								1x 1/162, 3x 2/162, 1x 2/179, 1x 3, 1x 5, 2x 7						
(216) Bilirubin direct	[μmol/L]				87							77	72	94
Sample A		37,5	7,4	20	87							77	72	94
(1) Jendrassik - Gróf; (60) Roche		36,6	2,2	6,1	7	0	CVPG	34,5	1,4	18%	28,2	40,8	7	
(2) DCA, DPD; (1) Abbott		31,1	0,79	2,5	11	0	CVPG	31,3	0,73	18%	25,6	37	11	
(2) DCA, DPD; (58) Beckman Coulter (AU)		48,6	2,9	6	14	0	CVPG	48,8	1,8	18%	40	57,6	14	
(2) DCA, DPD; (60) Roche		34,2	3,5	10	32	0	CVPG	34,5	1,4	18%	28,2	40,8	32	
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		42,8	6,2	14	8	0	CVPG	39,8	3	18%	32,6	47	8	
Other					15	0							5	
								4x 0/0, 1x 1/1, 1x 1/58, 1x 1/158, 3x 2/162, 1x 7/70, 4x 7/179						
Sample B		53,1	9,3	18	87							77	72	94
(1) Jendrassik - Gróf; (60) Roche		52,5	2,9	5,5	7	0	CVPG	49,3	2,1	18%	40,4	58,2	7	
(2) DCA, DPD; (1) Abbott		45,2	0,91	2	11	0	CVPG	45,5	0,83	18%	37,3	53,7	11	
(2) DCA, DPD; (58) Beckman Coulter (AU)		67,3	3,2	4,8	14	0	CVPG	67,4	1,9	18%	55,2	79,6	14	
(2) DCA, DPD; (60) Roche		48,7	5,5	11	32	0	CVPG	49,3	2,1	18%	40,4	58,2	32	
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		58,3	5,5	9,4	8	0	CVPG	57	2,9	18%	46,7	67,3	8	
Other					15	0							5	
								4x 0/0, 1x 1/1, 1x 1/58, 1x 1/158, 3x 2/162, 1x 7/70, 4x 7/179						